|By PR Newswire||
|February 11, 2013 09:39 AM EST||
HIGH WYCOMBE, England, February 11, 2013 /PRNewswire/ --
- Today, the SMC announced that Rienso has been accepted for restricted use within NHS Scotland for the treatment of iron deficiency anaemia (IDA) in non-haemodialysis dependent adult patients with chronic kidney disease (CKD) when oral iron preparations are ineffective or cannot be used
- The clinical efficacy and safety of Rienso has been assessed in over 1,500 subjects from its clinical development programme, and supported by observational data in more than 8,600 patients and 33,000 doses administered in clinical practice1-3
- Rienso offers a convenient and cost-competitive alternative for delivering a repletion course of IV iron, and requires fewer bolus injections over a shorter period of time when compared to most other IV iron preparations1,4-8
- Takeda looks forward to making Rienso available to patients in Scotland as part of its ongoing commitment to improving management of IDA
Today, Takeda UK announces the Scottish Medicines Consortium's (SMC) acceptance of Rienso (ferumoxytol), a new intravenous (IV) iron therapy to treat iron deficiency anaemia (IDA) restricted to non-haemodialysis dependent adult patients with chronic kidney disease (CKD) when oral iron preparations are ineffective or cannot be used. All eligible patients in NHS Scotland will now be able to receive Rienso, offering a convenient and cost-effective alternative to current IV iron therapies.1,4-8
"Rienso will be a valuable addition to the currently available therapies for IDA as an effective and convenient method for delivering high dose iron; a significant consideration for non-dialysis patients who maintain an independent lifestyle. Its acceptance by the SMC will be of real benefit to the Scottish renal community." - Professor Alan Jardine, University of Glasgow.
Anaemia continues to place a significant burden on the daily lives of CKD patients, despite the availability of treatments to address the condition.9 Effective and efficient delivery of high doses of IV iron can lead to less disruption to the daily life of CKD patients, brought about by less time spent away from their home, family and work.8 Additionally, fewer patient visits can help improve the efficiency of service delivery leading to cost savings for the NHS.8
Marketing authorisation for Rienso was granted by the European Commission on 15 June 2012.1 Administered as a rapid IV injection, Rienso can be given to most adults as two x 510 mg doses administered 2-8 days apart, the benefits of which are rapid repletion of iron stores in anaemic CKD patients, with fewer bolus injections when compared to most other IV iron preparations.1,4-8 Rienso also offers the NHS a cost-competitive solution when compared to the alternative high bolus dose IV iron.7
Iron deficiency is a common cause of anaemia often seen in the later stages of CKD, and can have a profound impact on patients' lives, causing fatigue, shortness of breath and an increase in the risk of cardiovascular (CV) complications including congestive heart failure.9 Management of IDA is therefore an important aspect of care for patients with CKD and in Scotland alone, over 11,000 non-haemodialysis dependent CKD patients are estimated to suffer from anaemia.10
"Takeda are committed to improving the lives of patients worldwide, particularly in CKD, a profoundly debilitating condition for the patients who suffer from it. Acceptance of Rienso by the SMC marks an important milestone in providing physicians with a valuable alternative in the management of CKD patients with IDA in Scotland." - Yasuhiro Fukutomi, Managing Director of Takeda UK.
Rienso has been shown in clinical studies to significantly increase haemoglobin levels, with a similar overall treatment-related adverse event rate as compared to oral iron across the spectrum of CKD; based on data from over 1,500 subjects.1 Compared to the most widely prescribed IV iron preparation, the FIRST (Ferumoxytol Compared to Iron Sucrose Trial) study demonstrated that Rienso, delivered as two injections of 510 mg within 2-8 days, had a similar safety and comparable efficacy profile to 1 g of iron sucrose dosed as 100 mg or 200 mg over 5 to 10 injections within 2-2.5 weeks.11
Moreover, these data are supported by additional retrospective analyses conducted in the United States involving more than 8,600 patients and more than 33,300 administered doses of Rienso.2,3
NOTES FOR EDITORS
Recommendation from the SMC
ADVICE: following a full submission
Ferumoxytol (Rienso®) is accepted for restricted use within NHS Scotland.
Indication under review: Intravenous treatment of iron deficiency anaemia in adult patients with chronic kidney disease.
SMC restriction: treatment of iron deficiency anaemia in non-haemodialysis dependent adult patients with chronic kidney disease when oral iron preparations are ineffective or cannot be used.
In two Phase III studies the mean increase from baseline in haemoglobin was significantly higher for ferumoxytol than oral iron in non-haemodialysis dependent patients with chronic kidney disease. A mixed treatment comparison demonstrated equivalent efficacy outcomes for ferumoxytol versus a range of intravenous iron preparations.
About Rienso® (ferumoxytol)
Ferumoxytol is an IV iron therapy with an approved indication for the treatment of IDA in adult patients with CKD. When patients are iron deficient ferumoxytol can be administered as an initial 510 mg intravenous injection, followed by a second 510 mg intravenous injection 2-8 days later. For patients with Hb ≤10 g/dL, or 10-12 g/dL and > 50 kg in body weight; the recommended course of ferumoxytol is two injections of 510 mg intravenous iron. Ferumoxytol significantly increases Hb levels in CKD patients with IDA, both on dialysis and in patients not on dialysis compared with oral iron. Clinical trials have also highlighted that ferumoxytol is well tolerated.1
Ferumoxytol was developed by AMAG Pharmaceuticals, Inc (AMAG).1 It received marketing approval as Feraheme from the United States Food and Drug Administration on June 30, 2009 and was commercially launched by AMAG in the United States shortly thereafter. Ferumoxytol received marketing approval in Canada in December 2011, in the European Union in June 2012 and in Switzerland in August 2012, where it will be marketed by Takeda as Rienso®.
A Summary of Product Characteristics is available on the website http://www.medicines.org.uk.
Takeda UK Ltd. is based in High Wycombe, Buckinghamshire and is the UK subsidiary of Takeda Pharmaceuticals Company, responsible for sales and marketing of the company's medicines in the UK.
Located in Osaka, Japan, Takeda Pharmaceutical Company is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine.
Further information about Takeda in the UK is available at http://www.takeda.co.uk.
- Rienso Summary of Product Characteristics (SmPC). Available online at: http://www.medicines.org.uk. Accessed January 2013.
- Schiller B, Bhat P, Sharma A, et al. Safety of Feraheme® (Ferumoxytol) in hemodialysis patients at 3 dialysis chains over a 1-year period. J Am Soc Nephrol 2011; 22: 477A-478A. Abstr FR-PO1573.
- Sharma A, Bhat P, Schiller B, et al. Efficacy of Feraheme® (Ferumoxytol) administration on target hemoglobin levels and other iron parameters across 3 dialysis chains. J Am Soc Nephrol 2011; 22: 485A. Abstr FR-PO1603.
- Venofer SmPC. Available online at: http://www.medicines.org.uk. Accessed January 2013.
- CosmoFer SmPC. Availabe online at: http://www.medicines.org.uk. Accessed January 2013.
- Monofer SmPC. Available online at: http://www.medicines.org.uk. Accessed January 2013.
- Monthly Index of Medical Specialities (MIMS). January 2013.
- Bhandari S. Beyond efficacy and safety - the need for convenient and cost-effective iron therapy in health care. NDT Plus 2011; 4(Suppl 1): i14-i19.
- O'Mara NB. Anemia in patients with chronic kidney disease. Diabetes Spectrum 2008; 21: 12-19.
- Scottish Intercollegiate Guidelines Network. Diagnosis and management of chronic kidney disease. 2008. Available online at: http://www.sign.ac.uk. Accessed January 2013.
- Macdougall IC, McLaughlin J, Fortin GS, Li Z, Strauss WE. The FIRST head-to-head comparison study (Ferumoxytol compared to Iron Sucrose Trial) of the safety and efficacy of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with chronic kidney disease. Presented November 2011 at ASN Kidney Week 2011.
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
Apr. 29, 2017 11:45 AM EDT Reads: 1,847
NHK, Japan Broadcasting, will feature the upcoming @ThingsExpo Silicon Valley in a special 'Internet of Things' and smart technology documentary that will be filmed on the expo floor between November 3 to 5, 2015, in Santa Clara. NHK is the sole public TV network in Japan equivalent to the BBC in the UK and the largest in Asia with many award-winning science and technology programs. Japanese TV is producing a documentary about IoT and Smart technology and will be covering @ThingsExpo Silicon Val...
Apr. 29, 2017 11:45 AM EDT Reads: 929
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
Apr. 29, 2017 11:15 AM EDT Reads: 2,361
Cloud Expo, Inc. has announced today that Aruna Ravichandran, vice president of DevOps Product and Solutions Marketing at CA Technologies, has been named co-conference chair of DevOps at Cloud Expo 2017. The @DevOpsSummit at Cloud Expo New York will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and @DevOpsSummit at Cloud Expo Silicon Valley will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Apr. 29, 2017 10:45 AM EDT Reads: 2,844
@DevOpsSummit at Cloud taking place June 6-8, 2017, at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long developm...
Apr. 29, 2017 09:45 AM EDT Reads: 2,466
Cloud promises the agility required by today’s digital businesses. As organizations adopt cloud based infrastructures and services, their IT resources become increasingly dynamic and hybrid in nature. Managing these require modern IT operations and tools. In his session at 20th Cloud Expo, Raj Sundaram, Senior Principal Product Manager at CA Technologies, will discuss how to modernize your IT operations in order to proactively manage your hybrid cloud and IT environments. He will be sharing be...
Apr. 29, 2017 09:45 AM EDT Reads: 990
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory?
Apr. 29, 2017 09:45 AM EDT Reads: 495
Five years ago development was seen as a dead-end career, now it’s anything but – with an explosion in mobile and IoT initiatives increasing the demand for skilled engineers. But apart from having a ready supply of great coders, what constitutes true ‘DevOps Royalty’? It’ll be the ability to craft resilient architectures, supportability, security everywhere across the software lifecycle. In his keynote at @DevOpsSummit at 20th Cloud Expo, Jeffrey Scheaffer, GM and SVP, Continuous Delivery Busine...
Apr. 29, 2017 08:45 AM EDT Reads: 1,299
While some vendors scramble to create and sell you a fancy solution for monitoring your spanking new Amazon Lambdas, hear how you can do it on the cheap using just built-in Java APIs yourself. By exploiting a little-known fact that Lambdas aren’t exactly single threaded, you can effectively identify hot spots in your serverless code. In his session at 20th Cloud Expo, David Martin, Principal Product Owner at CA Technologies, will give a live demonstration and code walkthrough, showing how to o...
Apr. 29, 2017 08:45 AM EDT Reads: 792
SYS-CON Events announced today that Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Juniper Networks challenges the status quo with products, solutions and services that transform the economics of networking. The company co-innovates with customers and partners to deliver automated, scalable and secure network...
Apr. 29, 2017 08:45 AM EDT Reads: 1,780
SYS-CON Events announced today that T-Mobile will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on ...
Apr. 29, 2017 07:15 AM EDT Reads: 1,532
Bert Loomis was a visionary. This general session will highlight how Bert Loomis and people like him inspire us to build great things with small inventions. In their general session at 19th Cloud Expo, Harold Hannon, Architect at IBM Bluemix, and Michael O'Neill, Strategic Business Development at Nvidia, discussed the accelerating pace of AI development and how IBM Cloud and NVIDIA are partnering to bring AI capabilities to "every day," on-demand. They also reviewed two "free infrastructure" pr...
Apr. 29, 2017 07:15 AM EDT Reads: 1,758
Everyone wants to use containers, but monitoring containers is hard. New ephemeral architecture introduces new challenges in how monitoring tools need to monitor and visualize containers, so your team can make sense of everything. In his session at @DevOpsSummit, David Gildeh, co-founder and CEO of Outlyer, will go through the challenges and show there is light at the end of the tunnel if you use the right tools and understand what you need to be monitoring to successfully use containers in your...
Apr. 29, 2017 05:45 AM EDT Reads: 2,326
SYS-CON Events announced today that Super Micro Computer, Inc., a global leader in compute, storage and networking technologies, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Supermicro (NASDAQ: SMCI), the leading innovator in high-performance, high-efficiency server technology, is a premier provider of advanced server Building Block Solutions® for Data Center, Cloud Computing, Enterprise IT, Hadoop/...
Apr. 29, 2017 05:30 AM EDT Reads: 2,584
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...
Apr. 29, 2017 05:00 AM EDT Reads: 1,594